OBJECTIVE: To summarise the current evidence of the significance and prognostic value of programmed cell death protein ligand 1 (PD-L1) expression in patients with non-muscle-invasive bladder cancer (NMIBC) treated with bacille Calmette-Guérin (BCG) immunotherapy. METHODS: A search was conducted in May 2020 of three electronic databases; MEDLINE, Scopus, and EMBASE. In this review we included results from original studies investigating the relationship between the PD-L1 expression and BCG response in patients with NMIBC. RESULTS: Only five relevant articles were identified in the literature to date. Some studies showed an association between increased PD-L1 expression and BCG unresponsiveness; however, other authors provided contradictory results and suggested that PD-L1 evaluation could not be used for reliable prediction of BCG response. CONCLUSIONS: The value of PD-L1 evaluation in predicting BCG response is debatable. Current evidence, based only on retrospective analyses, is inconsistent. Comparability of the results is diminished by the methodological limitations of immunohistochemistry assessment. Further multicentre, randomised trials are needed to make definitive conclusions. ABBREVIATIONS: ICs: immune cells; IHC: immunohistochemical staining; (N)MIBC: (non-) muscle-invasive bladder cancer; PD-L1: programmed cell death protein ligand 1; PD-1: programmed cell death protein 1; RC: radical cystectomy; TCs: tumour cells.
OBJECTIVE: To summarise the current evidence of the significance and prognostic value of programmed cell death protein ligand 1 (PD-L1) expression in patients with non-muscle-invasive bladder cancer (NMIBC) treated with bacille Calmette-Guérin (BCG) immunotherapy. METHODS: A search was conducted in May 2020 of three electronic databases; MEDLINE, Scopus, and EMBASE. In this review we included results from original studies investigating the relationship between the PD-L1 expression and BCG response in patients with NMIBC. RESULTS: Only five relevant articles were identified in the literature to date. Some studies showed an association between increased PD-L1 expression and BCG unresponsiveness; however, other authors provided contradictory results and suggested that PD-L1 evaluation could not be used for reliable prediction of BCG response. CONCLUSIONS: The value of PD-L1 evaluation in predicting BCG response is debatable. Current evidence, based only on retrospective analyses, is inconsistent. Comparability of the results is diminished by the methodological limitations of immunohistochemistry assessment. Further multicentre, randomised trials are needed to make definitive conclusions. ABBREVIATIONS: ICs: immune cells; IHC: immunohistochemical staining; (N)MIBC: (non-) muscle-invasive bladder cancer; PD-L1: programmed cell death protein ligand 1; PD-1: programmed cell death protein 1; RC: radical cystectomy; TCs: tumour cells.
Authors: Syed A Hussain; Alison Birtle; Simon Crabb; Robert Huddart; Diane Small; Maxwell Summerhayes; Robert Jones; Andrew Protheroe Journal: Eur Urol Oncol Date: 2018-07-02
Authors: Clara Delcourt; Pierre Gemival; François Xavier Nouhaud; Françoise Gobet; Andre Gillibert; Sophie Ferlicot; Jean Christophe Sabourin; Jacques Irani; Christian Pfister Journal: World J Urol Date: 2019-09-05 Impact factor: 4.226
Authors: Francesco Pierconti; Maria Rosaria Raspollini; Maurizio Martini; Luigi Maria Larocca; Pier Francesco Bassi; Riccardo Bientinesi; Gianna Baroni; Andrea Minervini; Guido Petracco; Giacomo Maria Pini; Carlo Patriarca Journal: Virchows Arch Date: 2020-02-07 Impact factor: 4.064
Authors: Johannes Breyer; Ralph M Wirtz; Wolfgang Otto; Philipp Erben; Thomas S Worst; Robert Stoehr; Markus Eckstein; Stefan Denzinger; Maximilian Burger; Arndt Hartmann Journal: Cancer Immunol Immunother Date: 2017-11-17 Impact factor: 6.968
Authors: Marko Babjuk; Maximilian Burger; Eva M Compérat; Paolo Gontero; A Hugh Mostafid; Joan Palou; Bas W G van Rhijn; Morgan Rouprêt; Shahrokh F Shariat; Richard Sylvester; Richard Zigeuner; Otakar Capoun; Daniel Cohen; José Luis Dominguez Escrig; Virginia Hernández; Benoit Peyronnet; Thomas Seisen; Viktor Soukup Journal: Eur Urol Date: 2019-08-20 Impact factor: 20.096
Authors: Max Kates; Andres Matoso; Woonyoung Choi; Alexander S Baras; Marcus J Daniels; Kara Lombardo; Aaron Brant; Nina Mikkilineni; David J McConkey; Ashish M Kamat; Robert S Svatek; Sima P Porten; Joshua J Meeks; Seth P Lerner; Colin P Dinney; Peter C Black; James M McKiernan; Chris Anderson; Charles G Drake; Trinity J Bivalacqua Journal: Clin Cancer Res Date: 2019-11-11 Impact factor: 12.531